Novartis’s China Sales Grow 25 Percent
This article was originally published in PharmAsia News
Novartis's China sales grew by 24.8 percent to reach 2.58 billion yuan ($362.7 million) in 2007; in particular, its animal health business jumped 50.9 percent. Beijing Novartis enjoyed sales of 2 billion yuan ($281 million), a rise of 27 percent. Six of Novartis's drug brands garnered over 100 million yuan ($14 million) each: anti-hypertensive medicine Diovan ranked number one in market share while sales of another anti-hypertensive Lotensin crossed 400 million yuan ($56.2 million). The company's vaccines introduced into China in mid-2006 reaped more than 50 million yuan ($7 million) in 2007. Novartis forecasts a growth of more than 20 percent for China in 2008. Its new R&D park in Shanghai is about to begin construction while its Suzhou plant will soon go into production. (Click here for more - Chinese Language)
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.